JAZZ vs SPGI · P/E 1988, rev $2.28B vs P/E 27, rev $15.34B
Jazz Pharmaceuticals PLC (JAZZ) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the JAZZ and SPGI stock pages for the full models.
Not investment advice.